AMGEN INVESTING MORE THAN HALF A BILLION DOLLARS IN NEW, STATE-OF-THE-ART CENTER FOR SCIENCE AND INNOVATION AT U.S. GLOBAL HEADQUARTERS

Rhea-AI Summary

Amgen (NASDAQ: AMGN) has announced plans to invest over $600 million in a new state-of-the-art center for science and innovation at its Thousand Oaks, California headquarters. The facility will enhance collaboration among researchers, engineers, and scientists, featuring advanced automation and digital capabilities.

The investment is part of Amgen's $40 billion+ commitment to U.S. manufacturing and R&D since 2017, including $5 billion in direct capital expenditures. Construction will begin in Q3 2025, creating hundreds of jobs. This announcement follows recent expansions including a $900 million facility in Ohio and a $1 billion plant in North Carolina.

Positive

• Investment of $600 million in new state-of-the-art research center demonstrates strong commitment to innovation
• Project will create hundreds of new U.S. jobs
• Part of larger $40 billion+ investment in U.S. manufacturing and R&D since 2017
• Additional recent investments include $900M in Ohio and $1B in North Carolina facilities
• Advanced automation and digital capabilities will enhance research capabilities

Negative

• Significant capital expenditure may impact short-term cash reserves
• Construction and integration period could temporarily affect operations

Insights

Biotechnology Investment Strategist

Amgen's $600M R&D center investment strengthens innovation capabilities while creating jobs and leveraging favorable tax policies for domestic expansion.

Amgen's $600 million investment in a new science and innovation center represents a significant commitment to strengthening its research infrastructure and maintaining its competitive edge in biotechnology. This capital allocation decision carries strategic importance beyond the headline figure.

The facility's focus on cross-disciplinary collaboration and advanced automation directly addresses a critical success factor in modern drug development - the need to accelerate discovery timelines through enhanced scientific collaboration and technology integration. In the highly competitive biotech landscape, companies that can rapidly translate research into viable drug candidates maintain crucial advantages.

This investment should be viewed in the broader context of Amgen's post-2017 capital allocation strategy. The company has deployed over $40 billion in manufacturing and R&D investments since tax reform, with $5 billion specifically directed to U.S. capital expenditures. The new center continues this domestic investment trend, alongside the $900 million Ohio manufacturing expansion and $1 billion North Carolina facility.

The creation of hundreds of construction jobs represents a positive regional economic impact, though the long-term employment effects from the center itself remain unspecified. The investment also strategically leverages tax incentives from the 2017 Tax Cuts and Jobs Act and the newer 2025 tax legislation, optimizing Amgen's capital deployment efficiency.

This infrastructure investment signals management's confidence in the company's long-term research pipeline and growth prospects, with facilities designed specifically to enhance collaboration across scientific disciplines - a model increasingly critical to developing complex biologic therapies.

Research and Development Infrastructure Investment Expected to Create Hundreds of U.S. Jobs 

THOUSAND OAKS, Calif., Sept. 2, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced plans to invest more than $600 million in a new, state-of-the-art center for science and innovation at its global headquarters in Thousand Oaks, California.

The center is designed to bring together researchers, engineers and scientists across disciplines to enhance collaboration and accelerate the discovery of next-generation therapeutics for patients with the most serious diseases. The building will feature advanced automation and digital capabilities, empowering scientists with the tools and environment needed to drive scientific excellence and advancements in biotechnology.

Amgen's long-standing commitment to U.S. innovation and state-of-the-art operations is reflected in more than $40 billion invested in manufacturing and research and development since the passage of the Tax Cuts and Jobs Act (TCJA) of 2017. This investment includes over $5 billion in direct capital expenditures in the U.S. The enactment of pro-growth tax policies in TCJA, extended and reinforced by the One Big Beautiful Bill Act of 2025, further facilitates Amgen's ability to invest domestically in cutting-edge science and manufacturing.

"At Amgen, we're continuing to invest in the future of American science and innovation," said Robert A. Bradway, chairman and chief executive officer at Amgen. "This new center will empower our scientists with the tools and collaborative environment they need to shape the next era of scientific discovery and advance medicines that improve human health."

The new center for science and innovation enhances the company's global network of sites, leveraging decades of operational expertise and technological advancements.

Construction is expected to begin in Q3 2025 and create hundreds of U.S. jobs. Amgen has been headquartered in Thousand Oaks, California, part of the greater Los Angeles region, since the company's founding more than 45 years ago.

The announcement builds on other recent investments from the company including a $900 million expansion of its manufacturing facility in Central Ohio and a $1 billion investment to build a second manufacturing plant in Holly Springs, North Carolina.

About Amgen 
Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases.

In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average^®, and it is also part of the Nasdaq-100 Index^®, which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization.

For more information, visit Amgen.com and follow Amgen on X, LinkedIn, Instagram, YouTube and Threads. 

Amgen Forward-Looking Statements
This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeOne Medicines Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla® (apremilast), our acquisitions of ChemoCentryx, Inc. or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, and any potential strategic benefits, synergies or opportunities expected as a result of such acquisition), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions, including those resulting from geopolitical relations and government actions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. There can be no guarantee that we will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. We may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of our information technology systems could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our sustainability objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all.

CONTACT: Amgen, Thousand Oaks
Elissa Snook, 609-251-1407 (media)
Adam Elinoff, 805-313-6285 (investors) 

View original content to download multimedia:https://www.prnewswire.com/news-releases/amgen-investing-more-than-half-a-billion-dollars-in-new-state-of-the-art-center-for-science-and-innovation-at-us-global-headquarters-302542364.html

SOURCE Amgen

FAQ

How much is Amgen investing in its new science and innovation center?

Amgen is investing more than $600 million in the new state-of-the-art center for science and innovation at its Thousand Oaks, California headquarters.

When will Amgen begin construction on its new research center?

Construction of the new center is expected to begin in Q3 2025 at Amgen's global headquarters in Thousand Oaks, California.

How many jobs will Amgen's new research center create?

The construction of Amgen's new center for science and innovation is expected to create hundreds of new U.S. jobs.

What is the total amount Amgen has invested in U.S. manufacturing and R&D since 2017?

Amgen has invested more than $40 billion in U.S. manufacturing and R&D since the Tax Cuts and Jobs Act of 2017, including over $5 billion in direct capital expenditures.

What other recent investments has Amgen made in U.S. facilities?

Amgen has recently invested $900 million in expanding its Central Ohio manufacturing facility and $1 billion to build a second manufacturing plant in Holly Springs, North Carolina.